Ident. | Authors (with country if any) | Title |
---|
000043 (2014) |
Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. Facheris | Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. |
000087 (2013) |
Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia Trenkwalder | AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. |
000098 (2012) |
Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. Moline | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. |
000157 (2011) |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
000206 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000217 (2010) |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease |
000219 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
000267 (2009) |
Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni] | Adherence to antiparkinson medication in a multicenter European study |
000308 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000312 (2007) |
Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France] | Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease |
000322 (2007) |
Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis] | Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease |
000360 (2006) |
Emmanuel Roze [France] ; Marie Vidailhet [France] ; Nenad Blau [Suisse] ; Lisbeth Birk Moller [Danemark] ; Diane Doummar [France] ; Thierry Billette De Villemeur [France] ; Anne Roubergue [France] | Long‐term follow‐up and adult outcome of 6‐pyruvoyl‐tetrahydropterin synthase deficiency |
000369 (2006) |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
000383 (2006) |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
000406 (2005) |
Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study |
000455 (2003) |
Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study |
000510 (2001) |
Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease |
000535 (1999) |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
000545 (1999) |
Yves Agid [France] ; E. Ahlskog [France] ; A. Albanese [France] ; D. Calne [France] ; T. Chase [France] ; J. De Yebenes [France] ; S. Factor [France] ; S. Fahn [France] ; O. Gershanik [France] ; C. Goetz [France] ; W. Koller [France] ; M. Kurth [France] ; A. Lang [France] ; A. Lees [France] ; P. Lewitt [France] ; D. Marsden [France] ; E. Melamed [France] ; P. P. Michel [France] ; Y. Mizuno [France] ; J. Obeso [France] ; W. Oertel [France] ; W. Olanow [France] ; Werner Poewe [France] ; Pierre Pollak [France] ; S. Przedzorski [France] ; N. Quinn [France] ; R. Raisman-Vozari [France] ; A. Rajput [France] ; F. Stocchi [France] ; E. Tolosa [France] | Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint |
000553 (1999) |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France] | The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease |
000556 (1999) |
Olivier Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |